160 related articles for article (PubMed ID: 33634422)
21. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.
Nizam W; Fackche N; Pessoa B; Kubi B; Cloyd JM; Grotz T; Fournier K; Dineen S; Veerapong J; Baumgartner JM; Clarke C; Patel SH; Wilson GC; Lambert L; Abbott DE; Vande Walle KA; Lee B; Raoof M; Maithel SK; Russell MC; Zaidi MY; Johnston FM; Greer JB
J Gastrointest Surg; 2022 Feb; 26(2):414-424. PubMed ID: 34506026
[TBL] [Abstract][Full Text] [Related]
23. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
24. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Baron E; Sardi A; King MC; Nikiforchin A; Lopez-Ramirez F; Nieroda C; Gushchin V; Ledakis P
Eur J Surg Oncol; 2023 Jan; 49(1):179-187. PubMed ID: 36253240
[TBL] [Abstract][Full Text] [Related]
26. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
27. Comparing Survival Outcomes and Impact of EPIC in Patients Undergoing CRS/HIPEC for Mucinous Appendiceal Neoplasm.
Mercado M; Shamavonian R; Cheng E; Ahmadi N; Morris DL
Anticancer Res; 2023 Feb; 43(2):817-822. PubMed ID: 36697077
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
[TBL] [Abstract][Full Text] [Related]
29. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit.
Bhutiani N; Grotz TE; Concors SJ; White MG; Helmink BA; Raghav KP; Taggart MW; Beaty KA; Royal RE; Overman MJ; Matamoros A; Scally CP; Rafeeq S; Mansfield PF; Fournier KF
Ann Surg Oncol; 2024 Jan; 31(1):614-621. PubMed ID: 37872456
[TBL] [Abstract][Full Text] [Related]
30. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
31. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms.
Valenzuela CD; Mangieri CW; Garland-Kledzik M; Gawdi R; Russell G; Perry KC; Votanopoulos KI; Levine EA; Shen P
Ann Surg Oncol; 2022 Jun; 29(6):3422-3431. PubMed ID: 35254575
[TBL] [Abstract][Full Text] [Related]
32. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative.
Beal EW; Srinivas S; Shen C; Kim A; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Grotz TE; Leiting JL; Fournier K; Dineen S; Powers B; Veerapong J; Kothari A; Maduekew U; Maithel S; Wilson GC; Patel SH; Lambert L; Abdel-Misih S; Cloyd JM
Ann Surg Oncol; 2023 Mar; 30(3):1840-1849. PubMed ID: 36310315
[TBL] [Abstract][Full Text] [Related]
33. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
[TBL] [Abstract][Full Text] [Related]
34. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
[TBL] [Abstract][Full Text] [Related]
35. A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC.
Lee RM; Gamboa AC; Turgeon MK; Zaidi MY; Kimbrough C; Leiting J; Grotz T; Lee AJ; Fournier K; Powers B; Dineen S; Baumgartner JM; Veerapong J; Mogal H; Clarke C; Wilson G; Patel S; Hendrix R; Lambert L; Pokrzywa C; Abbott DE; LaRocca CJ; Raoof M; Greer J; Johnston FM; Staley CA; Cloyd JM; Maithel SK; Russell MC
J Surg Oncol; 2021 Jan; 123(1):187-195. PubMed ID: 33002202
[TBL] [Abstract][Full Text] [Related]
36. Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.
Reghunathan M; Kelly KJ; Valasek MA; Lowy AM; Baumgartner JM
Ann Surg Oncol; 2018 Mar; 25(3):702-708. PubMed ID: 29282599
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.
Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA
Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583
[TBL] [Abstract][Full Text] [Related]
38. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
39. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
[TBL] [Abstract][Full Text] [Related]
40. Hyperthermic intraperitoneal chemotherapy in patients with incomplete cytoreduction for appendiceal pseudomyxoma peritonei: a 10-year treatment experience in China.
Wang B; Ma R; Shi G; Fan X; Rao B; Xu H
Orphanet J Rare Dis; 2024 Jan; 19(1):8. PubMed ID: 38178189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
